VolitionRx Limited Files 8-K Report
Ticker: VNRX · Form: 8-K · Filed: Jun 27, 2024 · CIK: 93314
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: VNRX
TL;DR
VNRX filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On June 27, 2024, VolitionRx Limited filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that VolitionRx Limited is providing updated information to the SEC, which could include financial details or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for disclosures and exhibits, not indicating any immediate negative events.
Key Players & Entities
- VolitionRx Limited (company) — Registrant
- June 27, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36833 (identifier) — Commission File Number
- 91-1949078 (identifier) — IRS Employer Identification Number
- 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (address) — Principal Executive Offices
- +1 (646) 650-1351 (phone_number) — Business Phone
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details are not provided in the excerpt.
What is the purpose of the Regulation FD Disclosure mentioned in the filing?
The Regulation FD Disclosure is a type of disclosure required by the SEC to prevent selective disclosure of material nonpublic information.
When was VolitionRx Limited incorporated, and in which jurisdiction?
VolitionRx Limited was incorporated in Delaware.
What is the principal executive office address for VolitionRx Limited?
The principal executive office is located at 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014.
Is there any indication of a material event or change in business operations in this filing?
The provided excerpt does not detail any specific material events or changes in business operations; it primarily lists the types of information being filed.
Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-27 09:24:11
Key Financial Figures
- $0.001 — hich Registered Common Stock,par value $0.001 per share VNRX NYSE American, LLC I
Filing Documents
- vnrx_8k.htm (8-K) — 30KB
- vnrx_ex991.htm (EX-99.1) — 15KB
- vnrx_ex992.htm (EX-99.2) — 39KB
- vnrx_ex992img2.jpg (GRAPHIC) — 50KB
- 0001477932-24-003896.txt ( ) — 288KB
- vnrx-20240627.xsd (EX-101.SCH) — 6KB
- vnrx-20240627_lab.xml (EX-101.LAB) — 14KB
- vnrx-20240627_cal.xml (EX-101.CAL) — 1KB
- vnrx-20240627_pre.xml (EX-101.PRE) — 9KB
- vnrx-20240627_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On June 27, 2024, VolitionRx Limited (the " Company ") issued a press release announcing the availability of the Company's mid-year review on the Investor Relations page of its website at https://ir.volition.com/ . Copies of the Company's press release and the mid-year review are furnished hereto as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and incorporated in this Item 7.01 in their entirety. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. The address for Volition's website is included in this document as an inactive textual reference only. The information contained in, or incorporated into, this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of VolitionRx Limited, dated June 27, 2024. 99.2 2024 Mid-Year Review, dated June 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date June 27, 2024 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 3 EXHIBIT INDEX Exhibit Number Description 99.1 Press Release of VolitionRx Limited, dated June 27, 2024. 99.2 2024 Mid-Year Review, dated June 27, 2024. 4